June 19, 2024
11 min listen
Save
Highlights from ASCO Annual Meeting 2024, Leukemia Edition
In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio’s top headlines from the meeting.
Jorge E. Cortes, MD, discusses how asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia. :27
Oreofe O. Odejide, MD, MPH, highlights the importance of this study. 3:30
Read the full coverage here:
New approach ‘redefining what is a suitable donor’ for stem cell transplant
Source: Al Malki MM, et al. Abstract 6503. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Cortes reports research funding to his institution from or consultant/advisory roles with Gilead Sciences, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and other companies.
